Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 125,800 shares, a drop of 70.6% from the November 15th total of 428,600 shares. Based on an average daily volume of 975,400 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.0% of the shares of the company are short sold.

Revelation Biosciences Stock Performance

Shares of NASDAQ REVB traded down $0.03 during mid-day trading on Wednesday, hitting $0.42. The stock had a trading volume of 477,142 shares, compared to its average volume of 951,517. The company has a 50 day moving average of $0.79 and a two-hundred day moving average of $1.24. Revelation Biosciences has a twelve month low of $0.40 and a twelve month high of $25.26. The firm has a market cap of $1.80 million, a PE ratio of -0.03 and a beta of 0.15.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.